Background
==========

Diabetes mellitus (DM) has very long historical accounts; it first points up in the medical text of several ancient cultures over 2000 year ago. According to the reports that, 135 million adults affected from the diabetes mellitus in year 1995 worldwide and the data will increase to 300 million in the year 2025 \[[@B1],[@B2]\]. Diabetes mellitus is a very common health problem arise worldwide rapidly, due changing the food habit, lifestyle and largely consumption of fast food. Major reason is generation of free radical formation, free radical generation caused by degeneration of carbohydrates, lipid and protein metabolism by increased blood glucose level (hyperglycaemia) resulting from the defects in insulin secretion, insulin action or both. Elevated glucose production causes oxidative stress and as a result there is increase in mitochondrial reactive oxygen species (ROS), non-enzymatic glycation of proteins and glucose autoxidation \[[@B3]\]. In diabetes, increased oxidative stress is due to generation of free radical and reduction of antioxidant defenses \[[@B4]\]. Endogenous antioxidant enzymes are responsible for the detoxification of injurious oxygen radicals. Evidences from epidemiological and biological studies have established that reactive oxygen species (ROS) are involved in a variety of physiological and pathological processes \[[@B5]\]. Different grades of synthetic drugs, herbal formulation available in the market therefore they are investigated with renewed interest all over the world \[[@B6],[@B7]\]. A lot of classes of synthetic drug are available in the market but quite a few herbal drugs are being employed in the treatment of diabetes mellitus. Only metformin is the one example of a drug which is obtained from the herb (*Galega officinalis*) with a very long history of use for diabetes. Still researching is going on to find out the more effective herbal drug to cure the diabetes and reduced the free radical formation with minimized side effect.

*Aegle marmelos* Correa. (Rutaceae) plant is found in all over India and also called as IndianQuince, holy fruit (According to Hindu mythology it is holy plant), Bengal quince, Golden Apple (English), ilvam (Tamil) Bilva, Sriphal, Shivadruma, Shivapala (Sanskrit) Bil (Gujarati), Bel (Bangali) and Beal (Hindi) \[[@B7]-[@B9]\]. Different parts of the plant (fruit, seed, leaves, root, bark and flowers) are used in preparation of various herbal preparations. The used of bael was having very long history. The most commonly used part is the fruit; fruit juice was strained and sweetened to make a drink similar to lemonade. In Ayurveda fruit are used for heart, stomach, intestinal tonic, chronic constipation and dysentery; some forms of indigestion, typhoid, debility, fever, hemorrhoids, hypochondria, melancholia and for heart palpitation. Various chemical constituents like Alkaloids, coumarins and steroids have been isolated and characterized from different part of the tree, such as leaves, fruit, wood, root and bark \[[@B10]\].

The present research exertion was taken up to evaluate the anti-diabetic activity of Umbelliferone β-D-galactopyranoside isolated from the stem bark of *Aegle marmelos* Correa. Since in the previous research \[[@B11]\] it was established that Umbelliferone is a potent free radical scavenger and works as antioxidant. Till date no study has been reported on the antioxidant activity of Umbelliferone β-D-galactopyranoside and the major root cause of diabetes mellitus is the development of free radicals which destroys the β-cells of the pancreatic islets \[[@B3]\], responsible for the secretion of insulin. Therefore, we have taken up the isolated compound for the evaluation against the diabetes, hyperlipidemia and oxidation.

Methods
=======

General
-------

Melting point was set up on a Veego, Model No. MPI is melting point apparatus and are uncorrected. ^1^H NMR spectra were recorded on Bruker Avance II 400 NMR Spectrophotometer and ^13^C NMR spectra on BrukerAvance II 100 NMR Spectrophotometer in DMSO using TMS as internal standard. Mass spectra were obtained on the VG-AUTOSPEC spectrometer. UV λmax (DMSO) were recorded on Shimadzu UV-1700 and FT-IR (in 2.0 cm-1, flat, smooth, Abex) were taken on Perkin Elmer -- Spectrum RX-I spectrophotometer.

Material
--------

The stem bark of *Aegle marmelos* Correa. collected from the botanical garden, Department of Pharmaceutical Sciences, Faculty of Health Sciences, Sam Higginbottom Institute of Agriculture, Technology & Sciences -- Deemed University and authenticated by Dr. Imran Kajmi (Pharmacognosist) and a specimen voucher (SIP/HD/054/12) of the plant sample respectively have been deposited in the herbarium of Siddhartha Institute of Pharmacy, Dehradun, Uttrakhand, India.

Chemical
--------

Silica gel (60--120 mesh) (Nicholas India Pvt. Ltd) and glass column were used for column chromatography. Streptozotocin (Sigma Chemical Co. USA), GOD/POD kit, Cholesterol kit, Triglyceride kit, (Span, India), Glibenclamide (purity \> 99%), Carboxyl methyl cellulose (SD fine, India), chemicals and other solvents used for the chromatography isolation and experimental protocol of analytical grade and were purchased from respective vendor, Allahabad, India.

Extraction and isolation
------------------------

The shade dry stem bark of *Aegle marmelos* Correa (2 kg) was extracted with methanol (5 L) at the 45°C for 72 h \[[@B12],[@B13]\]. After extraction total filtrate was concentrated to dryness in rotatory vacuum evaporator at 40°C to obtain slurry (322 gm). The slurry was dissolved in small amount of methanol and was absorbed on silica gel (60--120 mesh). It is subjected to silica gel column using as a C~6~H~14~/CHCl~3~/MeOH gradient system (1:0:0, 2:0:0, 4:0:0, 4:1:0, 1:1:0, 1:4:0, 1:6:0, 0:1:0, 0:48:0, 0:24:1, 0:48:2, 0:10:0, 0:10:1, 0:24:7, and 0:47:10; 3.0 L for each gradient system), yielding 22 fractions collected fraction spotted on pre coated silica gel TLC plate and the fraction having the same R~f~ value pooled together in 7 fractions. Fractions 2--4 (13.5 g) were combined separated on a silica gel column (CHCl~3~/MeOH, 3:1), and rechromatographed on a silica gel column (CHCl~3~/MeOH, 6:1 to 3:1), yielding 7 subtractions. Compound 1 was separated first by a normal phase silica gel column (CHCl~3~/MeOH, 3:1).

Animals
-------

Swiss albino wistar rats (150--220 g) was used for the study. The animals were housed under standard conditions of temperature (25 ± 1°C), relative humidity (55 ± 10%), 12 hr/12 hour light/dark cycles and animals were received standard pellet diet (Lipton rat feed, Ltd., Pune) with and water *ad libitum*. The experimental protocol was approved by the Institutional Animal Ethical Committee of Siddhartha Institute of Pharmacy (1435/PO/a/11/CPCSEA).

Acute toxicity study
--------------------

The toxicity study was conducted as per the guidelines of CPCSEA, article no 420. A separate experiment performed for determination of any toxic effect of the test drug. For acute toxicity study, normal healthy wistar rats were fasted overnight (16 hour) and randomly divided into different groups and each groups contain rats (n = 10). Wistar rat was treated with starting doses (0.05, 0.10, 0.50 and 0.100 g/kg body weight) of test compound and the control group was treated with vehicle alone (CMC 2%; 1 ml/kg body weight). All the animal groups allowed for food and water *ad libitum* and were observed over a period of 2 h for changing in various autonomical (defecation and urination), neurological (touch, reactivity, spontaneous, pain response and gait) and behavior (alertness, restlessness, irritability, and fearfulness) responses and after 24 and 48 h for mortality \[[@B14],[@B15]\]. If mortality caused by the compound within this period of the time was observed \[[@B16]\].

Assessment of UFG in oral glucose tolerance test
------------------------------------------------

Assessment of oral glucose tolerance test, healthy rats were divided into seven groups of six animals each \[[@B17]\].

Group I. Normal control rats received CMC.

Group II. Normal control rats received UFG (40 mg/kg p.o.).

Group III. Glucose (2 gm/kg) received rats.

Group IV. Glucose treated diabetic rats received UFG (10 mg/kg p.o.).

Group V. Glucose treated diabetic rats received UFG (20 mg/kg p.o.).

Group VI. Glucose treated diabetic rats received UFG (40 mg/kg p.o.).

Group VII. Glucose treated diabetic rats received glibenclamide (10 mg/kg p.o.).

All group animals received drug and vehicle orally. All the animals were received glucose (2 g/kg) 30 min after dosing. The blood sample was collected from puncture of retro-orbital of an eye; their glucose tolerance was studied up to 2 h at regular interval of 0, 30, 60, 120 min each.

Induction of diabetes
---------------------

Wistar rats were injected diabetes by a single intraperitoneal injection of streptozotocin (60 mg/kg body weight). Volume of STZ 1 ml/kg body weight prepared by STZ dissolving in freshly prepared 0.01 M citrate buffer (pH = 4. 5) \[[@B18]\]. After 3 days administration of STZ (streptozotocin) blood glucose level of rats were estimated. Rats with a blood glucose level of 220 mg/dL beyond considered as diabetic \[[@B19]\].

Experimental design
-------------------

Wistar rats were divided into seven groups and six animals in each group \[[@B20]\].

Group I. Normal control rats received citrate buffer (pH = 4.5) for 28 days (1 ml/kg p.o.).

Group II. Normal control rats received UFG (40 mg/kg p.o.) and continued for 28 days.

Group III. STZ-diabetic rats received vehicle only.

Group IV. STZ treated diabetic rats received UFG (10 mg/kg p.o.) and continued for 28 days.

Group V. STZ treated diabetic rats received UFG (20 mg/kg p.o.) and continued for 28 days.

Group VI. STZ treated diabetic rats received UFG (40 mg/kg p.o.) and continued for 28 days.

Group VII. STZ treated diabetic rats received glibenclamide (10 mg/kg p.o.) and continued for 28 days.

All groups animal received drug and vehicle orally, once daily. Blood was collected on the regular interval by retro-orbital puncture under mild an anesthesia and measure blood glucose level and collected blood sample was centrifuged and examined for plasma glucose analysis by a GOD - POD method using the Glucose Estimation Kit (Span Diagnostic, India).

Biochemical analysis
--------------------

After 28 days of treatment, blood sample was drawn from puncture the retro orbital under mild anesthesia condition, collected blood was centrifuged and examined for plasma glucose analysis by a GOD - POD method using the Glucose Estimation Kit (Span Diagnostic, India). Other serum estimation was done spectrophotometrically using standard kits which include serum insulin (Span Diagnostic, India), total cholesterol, HDL (High density lipoprotein) cholesterol (Span Diagnostic, India) and triglyceride (Span Diagnostic, India). Hexokinase, glucose-6-phosphate and fructose-1-6-biphosphatase was estimated by the reported method of Brandstrup and co-researcher \[[@B21]\].

Estimation of antioxidant enzymes
---------------------------------

For estimation of antioxidant enzymes, all group rats liver tissue was homogenized, centrifuged and examined for superoxide dismutase, catalase, glutathione peroxidase, malonaldehyde levels according to the reported methods with minor modification \[[@B22]-[@B25]\].

Histopathology
--------------

At 28 day all the animal sacrificed under mild anesthesia and different organ (heart, liver, pancreas and kidney) of the animal was isolated for histopathology studies. The isolated organ (heart, liver, pancreas and kidney) tissue fixed with 40% neutral buffered formalin, dehydrated by passing through a graded series of alcohol, embedded in paraffin blocks and then 5 mm sections were developed using a semi-automated rotatory microtome. Hematoxylin and eosin stain were used.

Statistical data analysis
-------------------------

All the data were expressed as the mean ± S. E. M. an analysis of variance (ANOVA) was used for the statistical analysis using Graph Pad Prism version 5.0. The values were considered to be significant when the P value was 0.001.

Result
======

Characterization of isolated compound
-------------------------------------

The methanolic extract of stem of *A. marmelos* was subjected to column chromatography. Fractions 40--60 were further purified by silica gel recolumn chromatography and the chromatography purified of these fractions led to the isolation of compound (500 mg). Isolated compound obtained as yellowish coloured solid compound (3 gm), mp -- 240°C, R~f~: 0.35, (C~7~H~8~/(C~2~H~5~)~2~O, 1:1), compound exhibited UV absorption bands at 330 nm (log ϵ 3.1), indicating coumarin derivative. ESI-MS at m/z (rel. int.): 324 \[M\]^+^ C~15~H~16~O~8~ (1.8), ^1^H NMR (DMSO-d~6~): 7.90 (1H, dd, J 9.6, 2.8 Hz, H -- 6), 7.51 (1H, d, J = 9.1 Hz, H - 4), 7.20 (1H, d, J = 2.8 Hz, H - 8), 6.91 (1H, d, J = 9.1 Hz, H - 3), 6.91 (1H, d, J = 9.6 Hz, H - 5), 5.12 (1H, d~1~, J = 7.2 Hz, H - 1^1^), 4.36 (1H, H - 5^1^), 3.82 (1H, H -2^1^), 3.78 (1H, H -3^1^), 3.67 (1H, H -4^1^), 3.16 (2H, H -6^1^). ^13^C NMR (DMSO-d~6~): 163.81 ( C-2), 112.06 (C-3), 142.75 (C-4), 128.14 (C-5), 124.32 (C-6), 157.64 (C-7), 103.25(C-8), 112.16 (C-9), 154.18 (C-10), 105.59 (C-1^I^), 74.19 (C-2^I^), 72.21 (C-3^I^), 68.63 (C-4^I^), 76.21 (C-5^I^), 62.05 (C-6^I^) (Table [1](#T1){ref-type="table"}). IR γ~max~ (KBr): 3435, 3390, 2936, 2851, 1702, 1607, 1515, 1458, 1425, 1337, 1278, 1224, 1115, 1071 cm^-1^ (Figure [1](#F1){ref-type="fig"}) (Additional File [1](#S1){ref-type="supplementary-material"}: Spectral Data of umbelliferone β-D-galactopyranoside).

![Structure of umbelliferone β-D-galactopyranoside.](1472-6882-13-273-1){#F1}

###### 

^**1**^**H and**^**13**^**C NMR values of Umbelliferone β-D-galactopyranoside**

   **Position**   ^**1**^**H**   ^**13**^**C**
  -------------- -------------- ---------------
        1              \-             \-
        2              \-           163.81
        3             6.91          112.06
        4             7.51          142.25
        5             6.38          128.14
        6             7.90          124.32
        7              \-           157.64
        8             7.20          103.25
        9              \-           112.16
        10             \-           154.18
       1^1^           5.12          105.59
       2^1^           3.82           74.19
       3^1^           3.78           72.21
       4^1^           3.47           68.63
       5^1^           4.36           76.21
       6^1^           3.16           62.05

Coupling constants in Hertz are provided in parenthesis.

Acute toxicity study
--------------------

An acute toxicity study revealed the non-toxic nature of the UFG. There was no lethality or any toxic reactions found at any of the doses selected until the conclusion of the study period.

Effect of UFG on oral glucose tolerance test
--------------------------------------------

The blood glucose level in rat fed on a normal diet (normal control, group I) was almost constant throughout the complete study. The normal control group rat received UFG (40 mg/kg) dose significantly showing the better utilization of glucose (Group II) as compared to the normal control group rat. Glucose induced higher blood glucose level group rat treated with different doses of UFG inhibit the high blood glucose level. Three different doses of UFG significantly (p \< 0.001) inhibit the high blood glucose level by 13.9%, 17.6% and 29.8% at the tested doses of 10 mg/kg, 20 mg/kg and 40 mg/kg respectively as shown in Figure [2](#F2){ref-type="fig"}. Glibenclamide (10 mg/kg) significantly (p \< 0.001) inhibit glucose excursion by 28% (Table [2](#T2){ref-type="table"}).

![**Effect of umbelliferone β-D-galactopyranoside on fasting plasma glucose on oral glucose tolerance test at different concentrations on STZ induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6;**^**c**^**P \< 0.05;**^**b**^**P \< 0.01;**^**a**^**P \< 0.001; P \> 0.05 is considered as non-significant (ns).**](1472-6882-13-273-2){#F2}

###### 

Effect of umbelliferone β-D-galactopyranoside on blood glucose levels in oral glucose tolerance test in normoglycemic rats

   **S. No.**        **Treatment**         **Dose**   **Mean blood glucose concentration ± SEM (mg/dl)**                                                        
  ------------ -------------------------- ---------- ---------------------------------------------------- ------------------------- --------------------------- ---------------------------
     **1**         **Normal Control**         \-                         87.2 ± 0.837                           87.2 ± 0.834               87.8 ± 0.735                87.8 ± 0.583
     **2**      **Normal Control + UFG**   40 mg/kg                      86.8 ± 0.735                           86.4 ± 0.734               84.4 ± 0.245                80.8 ± 0.583
     **3**        **Glucose Control**         \-                         88.8 ± 0.861                           140.4 ± 2.315               135 ± 1.143                 129 ± 1.963
     **4**             **UFG I**           10 mg/kg                      88.4 ± 0.734                       139.4 ± 1.158^**ns**^      127.8 ± 1.021^**\***^      106 ± 1.145^**\*\*\***^
     **5**             **UFG II**          20 mg/kg                      87.4 ± 1.077                        130 ± 1.158^**\***^      116.6 ± 1.435^**\*\***^    101.4 ± 1.032^**\*\*\***^
     **6**            **UFG III**          40 mg/kg                      88.8 ± 0.734                      124.8 ± 1.497^**\*\***^    109 ± 0.732^**\*\*\***^     87 ± 1.789^**\*\*\***^
     **7**         **Glibenclamide**       10 mg/kg                       89 ± 0.707                        125 ± 1.068^**\*\***^    111.4 ± 1.034^**\*\*\***^   88.6 ± 1.568^**\*\*\***^

All values represent mean ± SEM **\****P \<* 0.05; **\*\****P \<* 0.01; **\*\*\****P \<* 0.001, ns \< non significant; ANOVA, followed by Dunnett's multiple comparison test.

Effect of UFG on blood glucose level
------------------------------------

The blood glucose level of the rat fed a normal diet (normal control) remain unchanged at throughout the experimental study (Group I). In the other group received normal fed and dose UFG 40 mg/kg (Group II) shown the blood glucose level near the normal control group rat. On the contrary, the blood glucose level of STZ induced diabetic rats was increased significantly (Group III). STZ diabetic rat treated with different doses of UFG shown significantly (P \< 0.001) lowering the blood glucose level at dose dependent manner shown in Table [3](#T3){ref-type="table"}. On the other hand, glibenclamide (10 mg/kg) significantly inhibit the blood sugar level (Figure [3](#F3){ref-type="fig"}).

![**Effect of umbelliferone β-D-galactopyranoside on fasting plasma glucose at different concentrations on STZ induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6;**^**c**^**P \< 0.05;**^**b**^**P \< 0.01;**^**a**^**P \< 0.001; P \> 0.05 is considered as non-significant (ns).**](1472-6882-13-273-3){#F3}

###### 

Effect of umbelliferone β-D-galactopyranoside on biochemical parameters in STZ-induced diabetic rats

   **S. No.**               **Biochemical parameter**                **Normal control**   **Normal control + UFG (40 mg/kg)**   **STZ-diabetic control**^**a**^   **STZ diabetes + UFG (10 mg/kg)**^**b**^   **STZ diabetes + UFG (20 mg/kg)**^**b**^   **STZ diabetes + UFG (40 mg/kg)**^**b**^   **STZ diabetes + glibenclamide**^**b**^
  ------------ ---------------------------------------------------- -------------------- ------------------------------------- --------------------------------- ------------------------------------------ ------------------------------------------ ------------------------------------------ -----------------------------------------
     **1**              **Fasting plasma glucose (mg/dL)**              91.2 ± 1.114                 87.6 ± 1.031                  394.2 ± 3.992^**\*\*\***^              193.2 ± 1.393^**\*\***^                   166.2 ± 2.332^**\*\*\***^                  123.4 ± 2.379^**\*\*\***^                  136.4 ± 1.99^**\*\*\***^
     **2**              **Fasting Plasma Insulin (μU/mL)**              11.2 ± 0.374                 12.2 ± 0.374                   2.8 ± 0.383^**\*\*\***^                 4.4 ± 0.509^**\***^                       6.8 ± 0.374^**\*\***^                     9.4 ± 0.519^**\*\*\***^                    8.6 ± 0.609^**\*\*\***^
     **3**              **Glycated Heamoglobin (A1c) (%)**              1.4 ± 0.141                  1.36 ± 0.157                   4.82 ± 2.49^**\*\*\***^                 3.8 ± 0.184^**\***^                       3.42 ± 0.182^**\*\***^                    1.86 ± 0.161^**\*\*\***^                  2.04 ± 0.212^**\*\*\***^
     **4**               **Hexokinase (μg/mg of tissue)**              150.4 ± 3.356                  152 ± 3.146                  100.8 ± 1.655^**\*\*\***^              112.6 ± 1.778^**\*\***^                    127.6 ± 1.327^**\*\***^                   141.2 ± 1.934^**\*\*\***^                   139 ± 1.225^**\*\*\***^
     **5**        **Glucose-6-Phosphatase (unit/mg of tissue)**          10 ± 0.948                   10 ± 1.095                   15.4 ± 0.509^**\*\*\***^                 14.4 ± 0.612^**ns**^                       12.8 ± 0.374^**\***^                     10.8 ± 0.583^**\*\*\***^                  11.6 ± 0.244^**\*\*\***^
     **6**      **Fructose-1-6-biphosphatase (unit/mg of tissue)**      30.8 ± 0.861                 29.80 ± 0.489                 54.6 ± 2.619^**\*\*\***^                 47.4 ± 1.166^**\***^                      38.2 ± 1.281^**\*\***^                    32.2 ± 0.861^**\*\*\***^                  34.8 ± 0.583^**\*\*\***^
     **7**                **Total Cholesterol (mg/dL)**                 66.6 ± 1.503                 64.8 ± 1.655                  155.8 ± 3.865^**\*\*\***^               97.2 ± 1.158^**\*\***^                     82.2 ± 2.417^**\*\***^                    61.2 ± 2.131^**\*\*\***^                  66.2 ± 1.463^**\*\*\***^
     **8**                  **Triglycerides (mg/dL)**                   82.4 ± 3.231                  80 ± 1.378                   154.6 ± 1.161^**\*\*\***^               131.8 ± 1.163^**\***^                     123.2 ± 1.660^**\*\***^                    96.2 ± 1.392^**\*\*\***^                  108.4 ± 1.071^**\*\*\***^
     **9**              **Total HDL Cholesterol (mg/dL)**               58.6 ± 1.913                 59.8 ± 4.266                  30.8 ± 1.319^**\*\*\***^                 42.8 ± 1.356^**\***^                      50.4 ± 0.927^**\*\***^                    59.2 ± 1.068^**\*\*\***^                  55.8 ± 1.167^**\*\*\***^
     **10**             **Total LDL Cholesterol (mg/dL)**               37.9 ± 1.206                 33.4 ± 1.188                   197 ± 6.647^**\*\*\***^               118.5 ± 1.201^**\*\***^                    65.5 ± 1.391^**\*\*\***^                   44.4 ± 1.668^**\*\*\***^                  61.8 ± 1.559^**\*\*\***^
     **11**             **Total VLDL Cholesterol (mg/dL)**             16.48 ± 0.326                  16 ± 0.276                   30.92 ± 0.647^**\*\*\***^               26.36 ± 0.232^**\***^                     24.72 ± 0. 331^**\*\***^                  19.24 ± 0.279^**\*\*\***^                  21.68 ± 0.215^**\*\*\***^
     **12**                 **Weight Variation (g) ±**                  196 ± 0.775                  197.6 ± 1.288                 165.2 ± 3.382^**\*\*\***^             190.4 ± 4.686^**\*\*\***^                   195 ± 3.761^**\*\*\***^                   203.2 ± 4.428^**\*\*\***^                  183.4 ± 5.269^**\*\*\***^

All values represent mean ± SEM **\****P \<* 0.05; **\*\****P \<* 0.01; **\*\*\****P \<* 0.001, ns \< non significant; ANOVA, followed by Dunnett's multiple comparison test.

^a^Compared to vehicle control.

^b^Compared to diabetic control.

Effect of UFG of plasma insulin
-------------------------------

The levels of plasma insulin in diabetic groups were significantly decreased as compared to the normal control group and UFG dose 40 mg/kg treated normal control group rat (Table [3](#T3){ref-type="table"}). Different doses of UFG (10 mg/kg, 20 mg/kg and 40 mg/kg) and glibenclamide (10 mg/kg) received groups significantly (p \< 0.001) increase the level of plasma insulin. The result suggests that the plasma insulin level of UFG 40 mg/kg maximum increase when compare with the 10 mg/kg, 20 mg/kg and glibenclamide (Figure [4](#F4){ref-type="fig"}).

![**Effect of umbelliferone β-D-galactopyranoside on level of plasma insulin at different concentrations on STZ induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6;**^**c**^**P \< 0.05;**^**b**^**P \< 0.01;**^**a**^**P \< 0.001; P \> 0.05 is considered as non-significant (ns).**](1472-6882-13-273-4){#F4}

Effect of UFG on total cholesterol
----------------------------------

To evaluate the effect of UFG on total cholesterol level, the diabetic rat received different doses (10 mg/kg, 20 mg/kg and 40 mg/kg) of UFG and glibenclamide (10 mg/kg). The level of cholesterol increases in diabetic rat as compared to the normal control group and UFG dose 40 mg/kg treated normal control group rat (Table [3](#T3){ref-type="table"}). Different doses of UFG (10 mg/kg, 20 mg/kg and 40 mg/kg) and glibenclamide (10 mg/kg) received group decreasing the level of total cholesterol as compared to the diabetic control groups rat. UFG dose 40 mg/kg is more effective to decrease the level of total cholesterol as compared to other group treated with different doses of UFG (10 mg/kg, 20 mg/kg) and glibenclamide (Figure [5](#F5){ref-type="fig"}).

![**Effect of umbelliferone β-D-galactopyranoside on level of total cholesterol at different concentrations on STZ induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6;**^**c**^**P \< 0.05;**^**b**^**P \< 0.01;**^**a**^**P \< 0.001; P \> 0.05 is considered as non-significant (ns).**](1472-6882-13-273-5){#F5}

Effect of UFG on triglyceride
-----------------------------

The level of triglyceride is increased in STZ induced diabetic rat as compared to the normal control group and UFG dose 40 mg/kg treated normal control group rat (Table [3](#T3){ref-type="table"}). Increase the level of triglyceride in STZ induced diabetic group, treated with different doses of UFG (10 mg/kg, 20 mg/kg and 40 mg/kg) and glibenclamide (10 mg/kg) significantly inhibit the level of triglyceride. UFG 40 mg/kg is most effective in dose on inhibiting the maximum level of triglyceride as compared to 10 mg/kg, 20 mg/kg doses of UFG and glibenclamide (Figure [6](#F6){ref-type="fig"}).

![**Effect of umbelliferone β-D-galactopyranoside on level of triglyceride at different concentrations on STZ induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6;**^**c**^**P \< 0.05;**^**b**^**P \< 0.01;**^**a**^**P \< 0.001; P \> 0.05 is considered as non-significant (ns).**](1472-6882-13-273-6){#F6}

Effect of UFG on total HDL (high density lipoprotein) cholesterol
-----------------------------------------------------------------

To evaluate the effect of UFG on total HDL cholesterol, the level of HDL cholesterol was decreased in STZ treated diabetic rat as compared to the normal control group and UFG dose 40 mg/kg treated normal control group rat (Table [3](#T3){ref-type="table"}). The effect of different doses of UFG (10 mg/kg, 20 mg/kg and 40 mg/kg) and glibenclamide (10 mg/kg) significantly increases the level of HDL cholesterol. UFG 40 mg/kg doses shown the maximum increasing the level of HDL cholesterol as compared to 10 mg/kg, 20 mg/kg doses of UFG and glibenclamide (10 mg/kg) treated group (Figure [7](#F7){ref-type="fig"}).

![**Effect of umbelliferone β-D-galactopyranoside on level of HDL (High density lipoprotein) cholesterol at different concentrations on STZ induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6;**^**c**^**P \< 0.05;**^**b**^**P \< 0.01;**^**a**^**P \< 0.001; P \> 0.05 is considered as non-significant (ns).**](1472-6882-13-273-7){#F7}

Effect of UFG on total LDL (low density lipoprotein) cholesterol
----------------------------------------------------------------

In STZ induced diabetic rat increased the level of LDL cholesterol as compared to the normal control group and UFG dose 40 mg/kg treated normal control group rat. The effect of different doses of UFG and glibenclamide in STZ induced diabetic rat significantly (P \< 0.001) inhibit the increased level of LDL cholesterol (Table [3](#T3){ref-type="table"}). The maximum decreasing the LDL cholesterol level was appeared in the group received UFG 40 mg/kg (Figure [8](#F8){ref-type="fig"}).

![**Effect of umbelliferone β-D-galactopyranoside on level of LDL (Low density lipoprotein) cholesterol at different concentrations on STZ induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6;**^**c**^**P \< 0.05;**^**b**^**P \< 0.01;**^**a**^**P \< 0.001; P \> 0.05 is considered as non-significant (ns).**](1472-6882-13-273-8){#F8}

Effect of UFG on total VLDL (very low density lipoprotein) cholesterol
----------------------------------------------------------------------

To evaluate the effect of UFG on VLDL (very low density lipoprotein) cholesterol, in STZ induced diabetic rat increased the level of VLDL cholesterol as compared to the normal control group and UFG dose 40 mg/kg treated normal control group rat. Diabetic rat treated with different doses of UFG and glibenclamide significantly (P \< 0.001) decreasing the level of VLDL cholesterol. Diabetic rats treated with UFG 40 mg/kg showed the maximum augmentation in the level of VLDL cholesterol as compared to other groups received different doses of UFG and glibenclamide (Figure [9](#F9){ref-type="fig"}).

![**Effect of umbelliferone β-D-galactopyranoside on level of VLDL (very low density lipoprotein) cholesterol at different concentrations on STZ induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6;**^**c**^**P \< 0.05;**^**b**^**P \< 0.01;**^**a**^**P \< 0.001; P \> 0.05 is considered as non-significant (ns).**](1472-6882-13-273-9){#F9}

Effect of UFG on hexokinase
---------------------------

The level of hexokinase decrease in STZ treated group as compared to the normal control group and UFG dose 40 mg/kg treated normal control group rat (Table [3](#T3){ref-type="table"}). Diabetic groups rat treated with different doses of UFG (10 mg/kg, 20 mg/kg and 40 mg/kg) and glibenclamide (10 mg/kg) significantly increase the level of hexokinase. Diabetic rat treated with dose 40 mg/kg UFG show maximum growth in the level of hexokinase as compared to other groups received 10 mg/kg, 20 mg/kg dose of UFG and glibenclamide (Figure [10](#F10){ref-type="fig"}).

![**Effect of umbelliferone β-D-galactopyranoside on level of Hexokinase at different concentrations on STZ induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6;**^**c**^**P \< 0.05;**^**b**^**P \< 0.01;**^**a**^**P \< 0.001; P \> 0.05 is considered as non-significant (ns).**](1472-6882-13-273-10){#F10}

Effect of UFG on glucose-6-phosphate
------------------------------------

To evaluate the effect of different doses of UFG on glucose-6-phosphate on diabetic rat (Table [3](#T3){ref-type="table"}). The level of glucose-6-phosphate was significantly increased in diabetic groups rat when compared to the normal control group and UFG dose 40 mg/kg treated normal control group rat. Diabetic rat treated with different doses of UFG (10 mg/kg, 20 mg/kg and 40 mg/kg) and glibenclamide (10 mg/kg) significantly decrease the level of glucose-6-phosphate. UFG 40 mg/kg dose shown a maximum increase in the level of glucose-6-phosphate when compared to 10 mg/kg, 20 mg/kg dose of UFG and glibenclamide (10 mg/kg) dose received groups (Figure [11](#F11){ref-type="fig"}).

![**Effect of umbelliferone β-D-galactopyranoside on level of Glucose-6-phosphatase at different concentrations on STZ induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6;**^**c**^**P \< 0.05;**^**b**^**P \< 0.01;**^**a**^**P \< 0.001; P \> 0.05 is considered as non-significant (ns).**](1472-6882-13-273-11){#F11}

Effect of UFG on fructose-1-6-biphosphatase
-------------------------------------------

The oral administration of different doses of UFG decreases the level of fructose-1-6-biphosphatase as compared to the normal control group and UFG dose 40 mg/kg treated normal control group rat. The level of fructose-1-6-biphosphatase increase in STZ induced diabetes (Table [3](#T3){ref-type="table"}). Diabetic groups received different doses of UFG (10 mg/kg, 20 mg/kg and 40 mg/kg) and glibenclamide (10 mg/kg) decrease the level of fructose-1-6-biphosphatase. The UFG dose 40 mg/kg shown the supreme diminish levels of fructose-1-6-biphosphatase comparison to other diabetic treated group received dose 10 mg/kg, 20 mg/kg dose of UFG and glibenclamide (Figure [12](#F12){ref-type="fig"}).

![**Effect of umbelliferone β-D-galactopyranoside on level of Fructose1-6-biphosphate at different concentrations on STZ induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6;**^**c**^**P \< 0.05;**^**b**^**P \< 0.01;**^**a**^**P \< 0.001; P \> 0.05 is considered as non-significant (ns).**](1472-6882-13-273-12){#F12}

Effect of UFG on glycated hemoglobin (A1c)
------------------------------------------

The level of glycated hemoglobin (A1c) increased in STZ-induced treated diabetic rats as compared to the normal control group and UFG dose 40 mg/kg treated normal control group rat (Table [3](#T3){ref-type="table"}). The treated group with different doses of UFG (10 mg/kg, 20 mg/kg and 40 mg/kg) and glibenclamide (10 mg/kg) significantly inhibit the level of glycated hemoglobin (A1c). UFG dose 40 mg/kg treated group significantly inhibits the level of glycated hemoglobin (A1c) as compared to 10 mg/kg, 20 mg/kg and glibenclamide (10 mg/kg) dose treated groups (Figure [13](#F13){ref-type="fig"}).

![**Effect of umbelliferone β-D-galactopyranoside on level of glycated hemoglobin (A1c)(%) at different concentrations on STZ induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6;**^**c**^**P \< 0.05;**^**b**^**P \< 0.01;**^**a**^**P \< 0.001; P \> 0.05 is considered as non-significant (ns).**](1472-6882-13-273-13){#F13}

Effect of UFG on malondialdehyde (MDA)
--------------------------------------

The level of MDA in untreated diabetic control rats was significantly higher than those in the normal control group and UFG dose 40 mg/kg treated normal control group rat (Table [4](#T4){ref-type="table"}). Different doses of UFG (10 mg/kg, 20 mg/kg and 40 mg/kg) administered groups significantly (p \< 0.001) inhibit the level of MDA. The maximum inhibition at the level of MDA seen in the group treated with 40 mg/kg of UFG. On the other hand standard drug (glibenclamide) also inhibits the increasing level of MDA in diabetic rats. The outcome suggests that UFG dose 40 mg/kg is more effective than the other doses of UFG and glibenclamide (Figure [14](#F14){ref-type="fig"}).

![**Effect of umbelliferone β-D-galactopyranoside on level of MDA (Malondialdehyde) cholesterol at different concentrations on STZ induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6;**^**c**^**P \< 0.05;**^**b**^**P \< 0.01;**^**a**^**P \< 0.001; P \> 0.05 is considered as non-significant (ns).**](1472-6882-13-273-14){#F14}

###### 

Effect on antioxidant enzyme at end of the study

  **S. No.**      **Biochemical parameter**     **Normal control**   **Normal control + UFG (40 mg/kg)**   **STZ-diabetic control**^**a**^   **STZ diabetes + UFD (10 mg/kg)**^**b**^   **STZ diabetes + UFD (20 mg/kg)**^**b**^   **STZ diabetes + UFD (40 mg/kg)**^**b**^   **STZ diabetes + glibenclamide**^**b**^
  ------------ ------------------------------- -------------------- ------------------------------------- --------------------------------- ------------------------------------------ ------------------------------------------ ------------------------------------------ -----------------------------------------
  **1**           **SOD (U/mg of protein)**       212.4 ± 2.839                  213 ± 2.608                  73.8 ± 4.005^**\*\*\***^               149.4 ± 5.391^**\*\***^                    175.2 ± 3.353^**\*\***^                   198.2 ± 3.247^**\*\*\***^                  202.6 ± 3.776^**\*\*\***^
  **2**           **CAT (U/mg of protein)**       135.8 ± 3.652                 136.6 ± 3.894                 60.8 ± 1.562^**\*\*\***^                  85 ± 3.286^**\***^                       97.8 ± 2.939^**\*\***^                   130.2 ± 3.397^**\*\*\***^                  129.2 ± 2.154^**\*\*\***^
  **3**         **GPx (nmole/mg of protein)**      33.2 ± 2.267                 34.2 ± 2.267                   14 ± 0.836^**\*\*\***^                  21 ± 0.707^**\*\***^                      24.6 ± 0.872^**\*\***^                    31.2 ± 1.068^**\*\*\***^                  28.8 ± 0.811^**\*\*\***^
  **4**         **MDA (nmole/mg of protein)**     0.241 ± 0.007                 0.222 ± 0.009                 0.522 ± 0.016^**\*\*\***^               0.396 ± 0.017^**\***^                     0.312 ± 0.008^**\*\***^                   0.274 ± 0.011^**\*\*\***^                  0.261 ± 0.014^**\*\*\***^

All values represent mean ± SEM **\****P \<* 0.05; **\*\****P \<* 0.01; **\*\*\****P \<* 0.001, ns \< non significant; ANOVA, followed by Dunnett's multiple comparison test.

a Compared to vehicle control.

b Compared to diabetic control.

Effect of UFG on glutathione peroxidase (GPx)
---------------------------------------------

The level of GPx was significantly (p \< 0.001) decreased in diabetic control groups as compared to the normal control group and UFG dose 40 mg/kg treated normal control group rat (Table [4](#T4){ref-type="table"}). Glibenclamide (10 mg/kg) and different doses of UFG (10 mg/kg, 20 mg/kg and 40 mg/kg) received groups significantly (p \< 0.001) increase the level of GPx. The outcome suggests that group which received UFG 40 mg/kg dose is increase the level of GPx as compared with other group rats received different doses of UFG and glibenclamide (Figure [15](#F15){ref-type="fig"}).

![**Effect of umbelliferone β-D-galactopyranoside on level of GPx (Glutathione peroxidase) cholesterol at different concentrations on STZ induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6;**^**c**^**P \< 0.05;**^**b**^**P \< 0.01;**^**a**^**P \< 0.001; P \> 0.05 is considered as non-significant (ns).**](1472-6882-13-273-15){#F15}

Effect of UFG on superoxide dismutase (SOD)
-------------------------------------------

The level of antioxidant enzyme SOD was significantly decreased in diabetic control groups as compared to the normal control group and UFG dose 40 mg/kg treated normal control group rat (Table [4](#T4){ref-type="table"}). Glibenclamide (10 mg/kg) and different doses of UFG (10 mg/kg, 20 mg/kg and 40 mg/kg) received groups significantly (p \< 0.001) increase the level of SOD. The outcome suggests that glibenclamide and all the doses of UFG increase the level of SOD, but UFG doses 40 mg/kg was more effective in increase the level of SOD in diabetic rat as compared with different doses of UFG and glibenclamide (Figure [16](#F16){ref-type="fig"}).

![**Effect of umbelliferone β-D-galactopyranoside on level of SOD (Superoxide dismutase) cholesterol at different concentrations on STZ induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6;**^**c**^**P \< 0.05;**^**b**^**P \< 0.01;**^**a**^**P \< 0.001; P \> 0.05 is considered as non-significant (ns).**](1472-6882-13-273-16){#F16}

Effect of UFG on catalase (CAT)
-------------------------------

The level of CAT were significantly (p \< 0.001) decreased in diabetic control groups when compared to the normal control group and UFG dose 40 mg/kg treated normal control group rat (Table [4](#T4){ref-type="table"}). Glibenclamide (10 mg/kg) and different doses of UFG (10 mg/kg, 20 mg/kg and 40 mg/kg) received groups rat significantly (p \< 0.001) increase the level of CAT. The data suggest that UFG 40 mg/kg dose was more effective to increase the level of CAT in diabetic rats as compared with other groups rat received different doses and glibenclamide (Figure [17](#F17){ref-type="fig"}).

![**Effect of umbelliferone β-D-galactopyranoside on level of CAT (Catalase) cholesterol at different concentrations on STZ induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6;**^**c**^**P \< 0.05;**^**b**^**P \< 0.01;**^**a**^**P \< 0.001; P \> 0.05 is considered as non-significant (ns).**](1472-6882-13-273-17){#F17}

Changes in body weight
----------------------

At the end of 28 days treatment, the body weight of normal rats, UFG dose 40 mg/kg treated normal rat, diabetic control, different doses of UFG and glibenclamide treated rats observed (Table [3](#T3){ref-type="table"}). Diabetic control group continued to lessen the weight till the conclusion of the study. Glibenclamide and UFG different doses (10 mg/kg, 20 mg/kg and 40 mg/kg) treated rats significantly increased the weight as compared to the diabetic control rats (Figure [18](#F18){ref-type="fig"}).

![**Effect of umbelliferone β-D-galactopyranoside on body weight at different concentrations on STZ induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6;**^**c**^**P \< 0.05;**^**b**^**P \< 0.01;**^**a**^**P \< 0.001; P \> 0.05 is considered as non-significant (ns).**](1472-6882-13-273-18){#F18}

Effect of UFG on liver
----------------------

Histopathology studies of STZ induced diabetic rat shown the accumulation of fat and large area of hepatocytes taken over by macro droplet of fat in the liver. Oral administration of different doses of UFG improved the histopathology conditions. UFG dose 10 mg/kg dose shown micro droplet of fat accumulation, another dose UFG 20 mg/kg dose shown some micro droplet of fat accumulation on rat histopathology. Dose UFG 40 mg/kg shown the rat liver histopathology similar to the glibenclamide drugs (Figures [19](#F19){ref-type="fig"} and [20](#F20){ref-type="fig"}).

![**Umbelliferone β-D-galactopyranoside (UFG) effect on liver in different groups of rats: (A) Normal control: Normal control group did not produce any changes in histopathology (B) Diabetic control: Diabetic control group rat shown enlarged of micro droplet of fat (yellow arrow) (C) UFG I (10 mg/kg): Treatment with UFG dose (10 mg/kg) shown some part having micro droplet of fat deposition (yellow arrow). (D)** UFG II (20 mg/kg): Treatment with different dose UFG (20 mg/kg) shown few particle of micro droplet of fat in liver histopathology (yellow arrow). **(E)** UFG III (40 mg/kg): Histopathology of UFG (40 mg/kg) drug not showing any fat deposition and other assortments. **(F)** Glibenclamide (10 mg/kg): Standard drug treated group shown histopathology similar to the normal control groups. The samples were obtained from the same liver anatomical regions. For each group, 6 rats were examined and 80 pictures were taken. The above picture for each group was chosen randomly from the 80 pictures in this group. Original magnification, 10 × .](1472-6882-13-273-19){#F19}

![**Effect of umbelliferone β-D-galactopyranoside (UFG) on liver in different groups of rat: (A) Normal control: Normal control group Shown normal histopathology (B) Diabetic control: In histopathology of diabetic control group rat shown overblown of micro droplet of fat (yellow arrow indicate) (C) UFG I (10 mg/kg): Histopathology of UFG dose (10 mg/kg) shown deposition of some micro droplet of fat (yellow arrow).(D)** UFG II (20 mg/kg): In the histopathology of dose UFG (20 mg/kg) showed few micro droplet deposition of fat (yellow arrow). **(E)** UFG III (40 mg/kg): Histopathology of UFG (40 mg/kg) drug not showing any fat deposition and other changes. **(F)** Glibenclamide (10 mg/kg): Histopathology of glibenclamide treated drug group shown similar to the normal control groups. The samples were obtained from the same liver anatomical regions. For each group, 6 rats were examined and 80 pictures were taken. The above picture for each group was chosen randomly from the 80 pictures in this group. Original magnification, 40 × .](1472-6882-13-273-20){#F20}

Effect of UFG on kidney
-----------------------

Study of STZ induced diabetes rat kidney histopathology shown inflammation in blood vessels, fat deposition, increase in the thickness of bowman capsules and change in size of the glomerulus. Treatment with different doses of UFG improves the injured rat kidney with increasing doses. The treatment with UFG 10 mg/kg dose showed improved kidney histopathology less inflammatory blood vessels, less fat deposition as compared to diabetic control. Treatment with UFG 20 mg/kg dose shown only fat deposition no inflamed blood vessels and the dose UFG 40 mg/kg shown the normal histopathology there is no inflammatory vessels and no fat deposition (Figures [21](#F21){ref-type="fig"} and [22](#F22){ref-type="fig"}).

![**Effect of umbelliferone β-D-galactopyranoside (UFG) on histopathology study of kidney in different groups of rat: (A) Normal control: Normal control group rat histopathology shown normal size of glomerulus (B) Diabetic control: Diabetic control rat histopathology shown inflammatory cell in blood vessels (blue arrow) and deposition of fats (yellow arrow) (C) UFG I (10 mg/kg): Tested drug UFG (10 mg/kg) treated group rat histopathology shown inflammation in blood vessels (brown arrow) and fat deposition (yellow arrow) (D) UFG II (20 mg/kg): Dose UFG (20 mg/kg) treated group rat histopathology shown only fat deposition (yellow arrow) no inflammatory blood cells. (E)** UFG III (40 mg/kg): Treatment with dose UFG (40 mg/kg) group rat histopathology shown kidney histopathology like the glibenclamide treated group **(F)** Glibenclamide (10 mg/kg): Histopathology of Glibenclamide treated group rat shown the normal kidney. The samples were obtained from the same liver anatomical regions. For each group, 6 rats were examined and 80 pictures were taken. The above picture for each group was chosen randomly from the 80 pictures in this group. Original magnification, 10 × .](1472-6882-13-273-21){#F21}

![**Effect of umbelliferone β-D-galactopyranoside (UFG) on histopathology of kidney normal and STZ treated groups rat: (A) Normal control: Average size of glomerulus shown in the normal group rat histopathology. (B)** Diabetic control: Inflammatory cells in blood vessels (blue arrow) and fat deposition (yellow arrow) shown in the histopathology of diabetic control group rat. **(C)** UFG I (10 mg/kg): Some inflammatory cell in blood vessels (blue arrow) and deposition of fat (yellow arrow) found in the histopathology of UFG I (10 mg/kg) treated groups' rat. **(D)** UFG II (20 mg/kg): Only fat deposition (yellow arrow) shown in the histopathology of UFG II (20 mg/kg) treated group rat. **(E)** UFG III (40 mg/kg): Histopathology of dose UFG (40 mg/kg) treated group rat shown average size of glomerulrs but slightly bigger in size as compared to the normal control. **(F)** Glibenclamide (10 mg/kg): Histopathology of glibenclamide treated group animal shown the histopathology similar to the normal kidney. The samples were obtained from the same liver anatomical regions. For each group, 6 rats were examined and 80 pictures were taken. The above picture for each group was chosen randomly from the 80 pictures in this group. Original magnification, 40 × .](1472-6882-13-273-22){#F22}

Effect of UFG on pancreas
-------------------------

Histopathology studies of pancreas of STZ induced diabetic rat displayed reduction of the islets of lengerhens, damaged or reduced the size of β cells and extensive necrosis changes followed by fibrosis and atrophy. STZ induced diabetic rat treated with different doses of UFG and glibenclamide restored the necrotic and fibrotic changes and raised the number of β cells (Figures [23](#F23){ref-type="fig"} and [24](#F24){ref-type="fig"}).

![**Effect of umbelliferone β-D-galactopyranoside (UFG) photomicrographs of histological changes in rat pancreas: (A) Normal control: Histological structure of normal control group rat pancreas showing the normal islet (white arrow) (B) Diabetic control: Focal necrosis (yellow arrow) showed in the histopathology of diabetic control group rat. (C)** UFG I (10 mg/kg): Treatment Histopathology of tested drug rat showing bigger size of islet and focal necrosis (yellow arrow) **(D)** UFG II (20 mg/kg): Histopathology of tested drug rat showing focal necrosis (yellow arrow) **(E)** UFG III (40 mg/kg): Histopathology of tested drug rat showing normal size of islet (white arrow) **(F)** Glibenclamide (10 mg/kg): glibenclamide treated rat pancreas showing normal islet (white arrow). For each group 6 rats were examined and 80 pictures were taken. The above picture for each group was chosen randomly from the 80 pictures in this group. Original magnification, 10 × .](1472-6882-13-273-23){#F23}

![**Effect of Umbelliferone β-D-galactopyranoside (UFG) photomicrographs of histological changes in rat pancreas: (A) Normal control: normal histological structure of rat pancreas showing normal islet (white arrow) (B) Diabetic control: Histopathology of diabetic control rat showing focal necrosis (yellow arrow) (C) UFG I (10 mg/kg): Histopathology of tested drug rat showing bigger size of islet and focal necrosis (yellow arrow) (D) UFG II (20 mg/kg): Histopathology of tested drug rat showing focal necrosis (yellow arrow) (E) UFG III (40 mg/kg): Histopathology of tested drug rat showing normal size of islet (white arrow) (F) Glibenclamide (10 mg/kg): glibenclamide treated rat pancreas showing normal islet (white arrow).** For each group 6 rats were examined and 80 pictures were taken. The above picture for each group was chosen randomly from the 80 pictures in this group. Original magnification, 40 × .](1472-6882-13-273-24){#F24}

Effect of UFG on heart
----------------------

Heart histopathology study of STZ induced diabetic rat shown increased the interstitial space, intercalated disc and level of fat deposition. Oral administration of UFG decreased the interstitial, intercalated disc and fat deposition at dose dependent manner. UFG dose 40 mg/kg was more effective to show normal histopathology of heart (Figures [25](#F25){ref-type="fig"} and [26](#F26){ref-type="fig"}).

![**Effect of Umbelliferone β-D-galactopyranoside (UFG) photomicrographs of histological change on heart in different groups of rats: (A) Normal control: Normal control group rat showing normal histopathology. (B)** Diabetic control: Increased interstitial space and distort the intercalated disc (yellow arrow) in diabetic control group rat histopathology. **(C)** UFG I (10 mg/kg): Dose UFG (10 mg/kg) treated group rat showing less interstitial space and intercalated disc (yellow arrow) **(D)** UFG II (20 mg/kg): Dose UFG (20 mg/kg) treated group rat showing only space in intercalated disc (yellow arrow). **(E)** UFG III (40 mg/kg): Dose UFG (40 mg/kg) treated group rat did not showing any changes in histopathology of heart. **(F)** Glibenclamide (10 mg/kg): Glibenclamide (5 mg/kg) treated drug shown the normal histopathology of heart. The samples were obtained from the same liver anatomical regions. For each group, 6 rats were examined and 80 pictures were taken. The above picture for each group was chosen randomly from the 80 pictures in this group. Original magnification, 10 × .](1472-6882-13-273-25){#F25}

![**Effect of Umbelliferone β-D-galactopyranoside (UFG) photomicrographs of histological on heart in different groups of rats: (A) Normal control: Histopathology of normal control group rat normal histopathology of heart (B) Diabetic control: Histopathology of diabetic control group rat shown increased interstitial space and distort the intercalated disc (yellow arrow) (C) UFG I (10 mg/kg): Histopathology of tested drug shown decreased interstitial space and intercalated disc (yellow arrow) (D) UFG II (20 mg/kg): Histopathology of tested drug shown less interstitial space (yellow arrow) (E) UFG III (40 mg/kg): Histopathology of tested drug shown normal heart like the glibenclamide (F) Glibenclamide (10 mg/kg): Histopathology of glibenclamide treated drug shown the normal histopathology of heart.** The samples were obtained from the same liver anatomical regions. For each group, 6 rats were examined and 80 pictures were taken. The above picture for each group was chosen randomly from the 80 pictures in this group. Original magnification, 40 × .](1472-6882-13-273-26){#F26}

Discussion
==========

The isolated compound was identified as umbelliferone β-D-galactopyranoside using different spectroscopy FT-IR, ESI-MS, ^1^H-NMR, ^13^C-NMR. IR absorption spectrum at 1702 cm^-1^ and the compound exhibit blue fluorescence and UV absorption maxima at 256, 277 and 330 NM for δ-lactone ring suggested coumarin nature of the isolated compound. On the basic of ^13^C NMR and mass spectrum ESI-MS at m/z (rel. int.): 324 \[M\]^+^ consistent with the molecular formula of C~15~H~16~O~8~. It also had IR absorption bands for hydroxyl groups (3435, 3390, 2936 cm^-1^), and an aromatic ring (1607, 1515 cm^-1^). The ^1^H NMR spectrum showed the presence of two AB-type double at δ 6.91 (J = 9. 1 Hz) and 7.51 (J = 9. 6 Hz) assigned to vinylic H-3 and H-4 protons, respectively. One-proton double douplet at δ 7.90 (J = 7.2, 2.8 Hz) and two on --proton doublets at δ 7.20 (J = 2.8 Hz) and 6.91 Hz (J = 9.1) was ascribed to coumarin H-6, H-8 and H-5 protons, respectively. One-proton doublets at δ 5.12 (J = 7.2 Hz) were accounted to α-oriented anomeric H-1^I^ protons, respectively. The other sugar protons resonated between δ 4.36 -- 3.16. The ^13^C NMR spectrum displayed signals for nine coumarin carbons in the range of δ 163.81 -- 103.25, anomeric carbon at δ 105.59 (C-1^I^) and other sugar carbons between δ 74.19 -- 62.05. The existence of an NMR H-2I signal in the deshielded region at δ 3.82 and carbon C-2^I^ signal at δ 74.19 indicated (2^I^ → 1^II^) linkage of the sugar units. The HMBC spectrum of the coumarin showed interactions of H-6, H-8 and H-1^I^ with C-7; H-3 and H-4 with C-2; and H-2^I^. The ^1^H and ^13^C NMR spectral data of the coumarin nucleus were compared with the reported data of other coumarins \[[@B26]-[@B28]\]. On the basis of spectral data analysis the structure of this new compound has been elucidated as Umbelliferone β-D-galactopyranoside. More than 100 compounds already isolated from the *Aegle marmelos* Correa but umbelliferone β-D-galactopyranoside isolated first time in this plant. Different part of the plant *Aegle marmelos* having the very long history to cure the diabetes but the lack of single bioactive compound was still unknown. In this manuscript we have isolated the bioactive compound UFG (umbelliferone β-D-galactopyranoside) from the bark and look into the antidiabetic activity in normal and diabetic rat models. The result showed that the different doses of UFG significantly decrease the blood sugar level, total cholesterol, total triglyceride, total HDL, LDL cholesterol of diabetes rats and demonstrated the antioxidant activity (SOD, CAT, GPx, MDA) as compared to diabetic control group and glibenclamide group rats.

STZ is a nitrosourea compound, widely used cytotoxic agent and obtained from the soil microbe *Streptomyces achromogenes,* which effect on pancreatic β-cells induced the diabetes \[[@B29]\]. STZ affects pancreatic β-cells, secreted on endogenous insulin which arrest stating the secretion of insulin; as a result the level of insulin increase in blood, due to increasing levels of insulin it increases the level of blood glucose \[[@B30]\].

The Wister rats treated with different doses of UFG orally exhibited normal behaviour till doses 100 mg/kg, these groups behave normally on touching and pain response. There was no lethality or any toxic reactions found with the selected dose until the conclusion of the field. The dose of the test drug has been selected on the basis of dose calibration curve methods.

Different category of synthetic oral hypoglycemic agents currently available in the treatment and control of NIDDM (non insulin dependent diabetes mellitus) including thiazolidinediones, sulphonylureas, biguanides, α -- glucosidase inhibitors. Glibenclamide (used as the reference hypoglycemic agent in this study) \[[@B31]\]. Glibenclamide is a sulphonylurea class of drug and the most probable mechanism of action is inducing insulin secretion.

OGTT in the wistar rat model showed that different doses of UFG significantly reduced the glucose excursion in a dose dependent manner. Normal control group unchanged at the end of the study but normal control treated with UFG (40 mg/kg) dose treated group shown better utilization of glucose as compared to the normal control. Different doses of UFG exhibited remarkable decreasing the blood sugar lowering effect in the glucose tolerance test. UFG dose 40 mg/kg is more effective than the glibenclamide (Figure [2](#F2){ref-type="fig"}).

The outcome suggests that diabetic control group severely causing hyperglycaemia as compared to the normal control group. Comparing with the different doses of UFG treated group rats significantly lowered the elevated blood glucose level (Figure [3](#F3){ref-type="fig"}). During this investigation elevation of fasting plasma glucose level in diabetic control group rats at the end of the 28 day experimental period significantly (P \< 0.001) observed. Different doses of UFG and glibenclamide treated diabetic rats showed significant (P \< 0.001) reduction of initial fasting plasma glucose level and increasing the serum insulin level (Figure [4](#F4){ref-type="fig"}). Thus, the possible mechanism of action of UFG is potentiating the insulin by increasing either the pancreatic secretion of insulin from the existing cells or by releasing the bound form. Type I and Type II diabetes patient suffered from atherosclerosis (Coronary artery disease) which may cause the death \[[@B32]\]. Not only the atherosclerosis and other factor like hypertriglyceridemia, hypercholesterolemia and hypertension may contribute the coronary artery disease \[[@B33]-[@B35]\]. The lipid abnormality is circulating diabetes and glucose intolerance (having tendency to develop the diabetes) patient by insensitivity of peripheral tissue of insulin \[[@B36]\]. In STZ induced diabetic rat significant (P \< 0.001) increase level of total cholesterol, total triglyceride, total VLDL cholesterol and decrease levels of HDL cholesterol was observed. The outcome of the experiment reveals that continue doses of UFG administered to animals for 28 days nearly normalized the lipid profile in diabetic induced group rats. Different doses of UFG treated diabetic rats, shows marked reduction in total cholesterol (Figure [5](#F5){ref-type="fig"}), total triglyceride (Figure [6](#F6){ref-type="fig"}), total HDL cholesterol ((Figure [7](#F7){ref-type="fig"}), LDL cholesterol (Figure [8](#F8){ref-type="fig"}) and elevate the level of VLDL cholesterol (Figure [9](#F9){ref-type="fig"}) showed the hypolipidemic effect of UFG. The most effective doses of UFG 40 mg/kg not only decreases the level of TC, TG, and LDL but also improved the cardioprotective lipid HDL. In normal metabolism insulin activates the enzyme lipoprotein lipase enzyme and triglyceride hydrolysis. In diabetic condition deficiency of insulin inactivated the both enzyme and causes the hypertriglyceridemia \[[@B37]\].

Another mechanism of action of UFG may be increasing the level of liver enzyme. The liver plays an important role in postprandial hyperglycemia and the synthesis of glycogen. Hexokinase, glucose-6-phosphate and fructose-1-6-biphosphatase are the enzyme found in the liver and they convert glucose into energy, utilize the glucose, synthesis of glycogen etc. In the liver, hexokinase convert glucose into glucose-6-phosphatase \[[@B38],[@B39]\]. In STZ induced diabetic rats inhibit the synthesis of glycogen and inhibit the level of hexokinase. Decreasing the level of hexokinase inhibits the conversion of glucose into glucose-6-phosphate and increasing the level of glucose in the blood \[[@B40]\]. The STZ induced diabetic rats treated with different doses of UFG and glibenclamide has increased the level of hexokinase and increase the utilization of glucose to energy conversion (Figure [10](#F10){ref-type="fig"}). In an earlier discussion it shows that glucose-6-phosphate regulates the glucose metabolism with the help of hexokinase. In STZ induced rats increased the level of glucose-6-phosphate, increasing levels of glucose-6-phosphate improves the activity of a gluconeogenetic enzyme and enhance the manufacturing of fats from carbohydrates, due to excess manufacturing of fats, it starts deposition on kidney and liver \[[@B41],[@B42]\]. STZ induced diabetic rats treated with different doses of UFG and glibenclamide had normalized the activity of glucose-6-phosphatase enzyme near to normal control by decreasing the enhanced level of glucose-6-phosphate. Another vital liver enzyme fructose-1-6-biphosphate play an important role in the glycolysis (conversion of glucose into energy) \[[@B43],[@B44]\]. STZ induced diabetic group rat showed the increase level of fructose-1-6-biphosphate. Due to increase level of the fructose-1-6-biphosphate decline the glycolysis and stop the conversion of glucose into energy. STZ induced diabetic groups treated with different doses of UFG and glibenclamide decreasing the elevated level of fructose-1-6-biphosphate and brought back to normal level (Figure [12](#F12){ref-type="fig"}).

STZ induced diabetic rats showed increase the level of glucose in the blood which adds to the RBC (red blood cells) in the N terminal of hemoglobin chain and starts the production of glycated hemoglobin. The level of glycated hemoglobin was increased up to 16% in diabetes mellitus \[[@B45]\]. Sometime glycated hemoglobin can be used as an indicator of metabolic control of diabetes since glycohemoglobin levels approach normal value in diabetes in metabolic control. In normal condition glycated hemoglobin makes up 3.4-5.8% of total hemoglobin and small volume of blood glucose. Only 4.5-6% of glycated hemoglobin covalently bonded to the RBC in hemoglobin \[[@B46]\]. In our research exertion the level of glycated hemoglobin was elevated more than 4 times higher in the normal control rats. STZ diabetic rats treated with different doses of UFG significantly lowering the higher level of glycated hemoglobin (Figure [13](#F13){ref-type="fig"}), which indicate the improved level of glycemic control.

Several method are involved in reactive oxygen species in diabetes, such as production of lipid peroxidation (LPO) and glucose autooxidation, protein glycation, formation of advanced glycation products and polyol pathway \[[@B47]\]. STZ induced diabetes destroy the pancreatic insulin secreting β-cells and cause enhancing the level of reactive oxygen species (ROS), increase level of ROS damaging the tissue in the body. In the production of ROS oxygen free radical (polyunsaturated fatty acids) play as significant role \[[@B48],[@B49]\], ROS react with all biological substances and cell membrane constituent, lead to increasing the level of lipid peroxidation. Increased level of LPO impairs membrane function by inhibiting the membrane fluidity and altering the activity of membrane bound enzymes and receptors \[[@B48]\]. The role of natural and synthetic antioxidant is alteration of this damage. The MDA (an indicator of LPO) increased the level in diabetic rat (Figure [14](#F14){ref-type="fig"}). STZ induced diabetic rat groups treated with different doses of UFG significantly decreased the level of MDA. Increase level of GPx (Glutathione Peroxidase) which lead to deactivation of LPO reactions (Figure [15](#F15){ref-type="fig"}). Another primary enzyme such as SOD is capable of changing the superoxide radical to hydrogen peroxide and CAT (catalase) is able to inhibit hydrogen peroxide and involved in detoxification of hydrogen peroxide concentrations. In our investigation the SOD, CAT and GPx level were significantly decreased and level of MDA was increased in the different doses of UFG treated groups (Figures [16](#F16){ref-type="fig"} and [17](#F17){ref-type="fig"}) \[[@B50]\].

The reduction in the body weight of diabetic rats was observed in the throughout study of diabetes. The weight was reduced due to gluconeogenesis (catabolism of proteins and fats). Diabetic condition increases the muscle destruction or degradation of structural proteins in catabolism of fats and protein \[[@B51]\]. Different doses and glibenclamide treated STZ induced diabetes groups rat increases the body weight and also demonstrates the protective effect against the controlling the muscle wasting (Figure [18](#F18){ref-type="fig"}).

Histopathology studies of STZ induced diabetic group rat well supported the antidiabetic effect showing a considerable regeneration in the β cells of the pancreas with treated with umbelliferone β-D-galactopyranoside at 40 mg/kg; p.o. the antidiabetic effect of umbelliferone β-D-galactopyranoside may be attributed to the positive influence on endocrine cells of the pancreas resulting in increased production of insulin.

Histopathology studies performed on the STZ induced diabetic rat kidney showed damage to the glomerulus, enhancement in the mucopolysaccharide deposition, thickened basement membrane and edematous proximal convoluted tubules were found. Oral treatment of UFG shown absent of the damage glomerulus, edematous proximal convoluted with increased in mucopolysaccharide deposition at dose dependent manner. The study was performed in shorter duration and this might be insufficient for significant vascular changes in the kidney of the diabetic rats. Different doses of UFG treated diabetic rat however showed healing features, which resembled that of a normal kidney.

Conclusions
===========

In conclusion, the present investigation indicates that umbelliferone β-D-galactopyranoside has significant antidiabetic, antihyperlipidemic and antioxidant activity in STZ induced diabetic rat. Therefore, umbelliferone β-D-galactopyranoside may be regarded as one of the major attributes for the antidiabetic potential of *Aegle marmelos* Correa. Thus, umbelliferone β-D-galactopyranoside can serve as a lead molecule for further development of drugs that can possess significantly antidiabetic, antihyperlipidemic and antioxidant activity. However, auxiliary investigations are required to experience the fully elucidate mechanism and clinical implications by which umbelliferone β-D-galactopyranoside decreases elevated blood glucose in diabetic rats.
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